Home Cart Sign in  
Chemical Structure| 6311-35-9 Chemical Structure| 6311-35-9
Chemical Structure| 6311-35-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of 6-Bromonicotinic acid

CAS No. :6311-35-9
Formula : C6H4BrNO2
M.W : 202.01
SMILES Code : OC(=O)C1=CC=C(Br)N=C1
MDL No. :MFCD01927100
InChI Key :JDJBRMNTXORYEN-UHFFFAOYSA-N
Pubchem ID :238932

Safety of 6-Bromonicotinic acid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Application In Synthesis of 6-Bromonicotinic acid

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 6311-35-9 ]
  • Downstream synthetic route of [ 6311-35-9 ]

[ 6311-35-9 ] Synthesis Path-Upstream   1~2

  • 1
  • [ 6311-35-9 ]
  • [ 168173-56-6 ]
References: [1] Journal of Medicinal Chemistry, 2012, vol. 55, # 7, p. 3201 - 3215.
  • 2
  • [ 6311-35-9 ]
  • [ 889676-37-3 ]
YieldReaction ConditionsOperation in experiment
81%
Stage #1: With 1,1'-carbonyldiimidazole In dimethyl sulfoxide at 20℃; for 16 h;
Stage #2: With ammonia In water; dimethyl sulfoxide at 0℃; for 1 h;
Preparation 66-Brom o-nicotinam ideTo a solution of 6-bromo-nicotinic acid (4.8g, 23.8 mmol) in dimethylsulfoxide (20ml) was added at room temperature carbonyldiimidazole (4.8g, 29.6 mmol), and the mixture stirred for 16 hours. To the mixture was added dropwise, with cooling in ice bath, 0.880 ammonia solution (40ml), then the mixture stirred for 1 hour, then poured into water (20ml). The precipitate was filtered, washed with water and dried in vacuo to give the title product as a white solid in 81percent yield, 3.9g.1 HNMR(DMSO-D6, 300MHz) δ: 7.66(br.s, 1H), 7.73(d, 1H), 8.09(m, 1H), 8.15(br.s, 1H), 8.78(d, 1 H). <n="20"/>micro analysis found (percent); C(36.00), 1-1(2.60), N(13.67); C6H5N2Br requires (percent); C(35.84), H(2.51), N(13.93)
79%
Stage #1: With 1,1'-carbonyldiimidazole In tetrahydrofuran at 20℃; for 3 h;
Stage #2: With ammonium hydroxide In tetrahydrofuran at 20℃;
A suspension of 6-Bromonicotinic acid (2 g) and CDI (1.8 g) in THF was stirred at room temperature. After 3 h the NH4OH (8 mL) were added dropwise to the mixture and stirred at room temperature overnight. Then, the solution was concentrated under reduced pressure. Light yellow solid. HPLC purity: 97.1percent. Yield: 79percent.
References: [1] Journal of Medicinal Chemistry, 2018, vol. 61, # 11, p. 4860 - 4882.
[2] Patent: WO2007/52124, 2007, A1, . Location in patent: Page/Page column 18-19.
[3] Bioorganic and Medicinal Chemistry Letters, 2017, vol. 27, # 17, p. 4150 - 4155.
 

Historical Records

Technical Information

Categories